Evidence map›Paper›PMID 41088952›Full record

ArticleEndocrinology and metabolism (Seoul, Korea)2025

Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus.

Noboru Kurinami, Masafumi Takada, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Kenji Ashida and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology and metabolism (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Noboru KurinamiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Masafumi TakadaDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Seigo SugiyamaDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Akira YoshidaDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Kunio HieshimaDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Tomoko SuzukiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Fumio MiyamotoDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Keizo KajiwaraDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Katsunori JinnouchiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
Kenji AshidaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
Masatoshi NomuraDivision of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
Hideaki JinnouchiDiabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tirzepatide has demonstrated greater efficacy than semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes mellitus (T2DM). However, the optimal tirzepatide dose following a switch from 1.0 mg of semaglutide remains unclear. This retrospective study included 15 T2DM patients who switched to tirzepatide due to inadequate weight loss. All patients started tirzepatide at 2.5 mg, with escalation to either 7.5 mg (n=10) or 10 mg (n=5). Changes in glycated hemoglobin (HbA1c) and body weight were assessed over a 3-month period. The 10 mg group experienced a significant reduction in HbA1c (-0.7%±0.3%, P<0.01) and a non-significant trend toward weight loss (-6.6±5.4 kg, P=0.07). In contrast, no significant changes were observed in the 7.5 mg group. There were no statistically significant differences between groups. Since 10 mg of tirzepatide significantly improved glycemic control after switching from 1.0 mg of semaglutide, early escalation to 10 mg may be beneficial for patients who respond inadequately to semaglutide.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsAgedBlood GlucoseDose-Response Relationship, DrugDrug SubstitutionFemaleFollow-Up StudiesGlucagon-Like Peptide 1Glycated HemoglobinHumansMaleMiddle AgedRetrospective StudiesSemaglutideBlood GlucoseGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutideTirzepatideBody weight reductionDiabetes mellitus, type 2Dose escalationSemaglutideTirzepatide

Identifiers

PMID41088952
PMCPMC12765867

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.